Earlier surgical intervention will play an increasingly important role in glaucoma management over the next several years. According to data from Market Scope, by 2027, the number of MIGS procedures is projected to double. Additionally, evidence for combined phacoemulsification and MIGS is growing.¹ Technologies like ELIOS can help us to expand the treatment base of physicians who offer MIGS and take advantage of the benefits of combined procedures. Lastly, long-term outcomes are increasingly important as patients live longer with the disease.

1. Montesano G, Ometto G, Ahmed IIK, et al.Five-year visual field outcomes of the HORIZON trial. Am J Ophthalmol. 2023;251:143-155.

Keith Barton, MD, FRCP, FRCS

• Consultant Ophthalmologist, Moorfields Eye Hospital, London
• Professor of Ophthalmology, UCL Institute of Ophthalmology, London
• Cofounder and Cochair of Ophthalmology Futures Forum and the International Glaucoma Surgery Registry
• Financial disclosure: Consultant (Elios Vision)